Maintenance immunosuppression in heart transplantation: insights from network meta-analysis of various immunosuppression regimens
- 18 May 2020
- journal article
- research article
- Published by Springer Nature in Heart Failure Reviews
- Vol. 27 (3) , 869-877
Abstract
Previous studies have reported superiority of mechanistic target-of-rapamycin (mTOR) antagonists (mTA) over calcineurin inhibitors (CNI) as part of maintenance immunosuppression (IS) in mitigating cardiac allograft vasculopathy (CAV) after heart transplantation (HT). MEDLINE and EMBASE were searched through October 2019 for studies comparing maintenance IS with mTA + antimetabolites (AM), CNI + mTA or CNI + AM post HT. The main outcomes were all-cause mortality, CAV, acute rejection, CMV infections, and change in eGFR. To compare different IS antagonists, a random-effects network meta-analysis was performed. We used p-scores to rank best treatments per outcome. Our search identified fifteen eligible studies (5 studies comparing mTA + AM vs. CNI + AM, 9 comparing CNI + mTA vs. CNI + AM, 1 comparing mTA + AM vs. CNI + mTA, 8 using everolimus and 7 sirolimus as mTA) reporting the selected outcomes. We did not identify any statistical difference in all-cause mortality among the three IS regimens without heterogeneity among studies. CAV rates were significantly lower with CNI + mTA (odds ratio [OR] 0.53, 95% confidence interval [CI] 0.3–0.92). Acute rejection rates were significantly lower with CNI + AM (OR 0.26, 95% CI 0.12–0.56) and with CNI + mTA (OR 0.16, 95% CI 0.07–0.33) compared with mTA + AM without significant heterogeneity (I2 = 43%, p = 0.9). CMV infections were significantly lower with mTA + AM (OR 0.13, 95% CI 0.03–0.46) and with CNI + mTA (OR 0.27, 95% CI 0.2–0.38) compared with CNI + AM without heterogeneity. mTA + AM led to higher eGFR compared with CNI + AM (9.06 ml/min/1.73 m2, 95% CI 3.15–14.97) and CNI + Mta (9.64 ml/min/1.73 m2, 95% CI 0.91–18.36), but the heterogeneity among studies was significant. CNI + mTA ranked better for CAV (p = 0.78), and acute rejection (p = 0.99) while mTA + AM for CMV infection (p = 0.94) and improvement in renal function (p = 0.93) than other regimens. Different IS regimens have similar effects on survival post HT, but CNI + mTA was associated with lower CAV rates, and acute rejection, while mTA + AM with less CMV infection post HT.Keywords
This publication has 29 references indexed in Scilit:
- A 1-Year Randomized Controlled Study of Everolimus Versus Mycophenolate Mofetil With Reduced-Dose Cyclosporine in Maintenance Heart Transplant RecipientsTransplantation Proceedings, 2013
- Randomized Controlled Trial of Sirolimus Conversion in Cardiac Transplant Recipients With Renal InsufficiencyAmerican Journal of Transplantation, 2012
- Sirolimus as Primary Immunosuppression Attenuates Allograft Vasculopathy With Improved Late Survival and Decreased Cardiac Events After Cardiac TransplantationCirculation, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Effect of Everolimus Introduction on Cardiac Allograft Vasculopathy—Results of a Randomized, Multicenter TrialTransplantation, 2011
- Surgical wound‐healing complications in heart transplant recipients treated with rapamycinWound Repair and Regeneration, 2007
- Cyclosporine Withdrawal Improves Renal Function in Heart Transplant Patients on Reduced-Dose Cyclosporine TherapyAmerican Journal of Transplantation, 2006
- Sirolimus-associated Interstitial Pneumonitis in 3 Heart Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2006
- Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 YearsCirculation, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003